Posts Archive

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...

Study CC-99712-MM-001 This is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical...

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04045795:...

CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...

AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...

DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...

NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients Study to Assess for Measurable Residual Disease (MRD)...

NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma Low-Dose Radiotherapy in...

NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255 in Relapsed/Refractory Multiple...

NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma NCT04000282: Phase 1:...

Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459 NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With...

DREAMM 9 - Transplant Ineligible - Newly Diagnosed Multiple Myeloma Part 1: Dose escalation and cohort expansion Part 2: Dose selection...

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

RRMM NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM) A Study of WVT078 in Patients With Multiple Myeloma...

NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in...

Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...